|
Gastrointestinal Stromal Tumors
|
|
0.010 |
GeneticVariation
|
BEFREE |
HQP1351, an orally bioavailable multikinase BCR-ABL inhibitor, is currently in clinical trials for the treatment of T315I mutant chronic myelogenous leukemia (CML), but the potential application in imatinib-resistant GISTs carrying secondary KIT mutations has not been explored.
|
31673329 |
2019 |
|
Central nervous system leukaemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Ponatinib therapy in recurrent philadelphia chromosome positive central nervous system leukemia with T315I mutation after allo-HSCT.
|
31785158 |
2019 |
|
Graft-vs-Host Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
|
28810255 |
2017 |
|
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
|
|
0.010 |
GeneticVariation
|
BEFREE |
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (CML).
|
26773037 |
2016 |
|
Philadelphia chromosome positive chronic myelogenous leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Leukemia cells escape BCR-ABL-targeted therapy by developing mutations, such as T315I, in the p210(BCR-ABL) fusion protein in Philadelphia chromosome-positive chronic myeloid leukemia (CML).
|
26846820 |
2016 |
|
Chronic eosinophilic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Resistance to imatinib in HES/CEL has been described mainly due to the T674I mutation in FIP1L1-PDGFRα, which is homologous to the imatinib-resistant T315I mutation in BCR-ABL.
|
25431951 |
2014 |
|
Idiopathic Hypereosinophilic Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
Resistance to imatinib in HES/CEL has been described mainly due to the T674I mutation in FIP1L1-PDGFRα, which is homologous to the imatinib-resistant T315I mutation in BCR-ABL.
|
25431951 |
2014 |
|
Philadelphia positive acute lymphocytic leukaemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
|
22587422 |
2012 |
|
Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
|
|
0.010 |
GeneticVariation
|
BEFREE |
In chronic myelogenous leukemia (CML)--chronic phase (CP), 5 had P-loop mutations and 3 had T315I mutations.
|
21239056 |
2011 |
|
Leukemogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190(BCR/ABL)-driven [including p210/p190(BCR/ABL)(T315I)] leukemogenesis without exerting any toxicity.
|
17717597 |
2007 |
|
Refractory cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, our study indicates that clinical resistance to nilotinib may be associated with the predominant emergence of T315I.
|
16614241 |
2006 |
|
Precursor B-cell lymphoblastic leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
Purinostat mesylate efficiently attenuated Ph<sup>+</sup> B-ALL progression and significantly prolonged the survival both in BL-2 secondary transplantation model with clinical patient symptoms of Ph<sup>+</sup> B-ALL, <i>BCR-ABL(T315I)</i>-induced primary B-ALL mouse model, and PDX model derived from patients with relapsed Ph<sup>+</sup> B-ALL post TKI treatment.
|
31439580 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients.
|
22587422 |
2012 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
This cell line may provide a useful model for in vitro and in vivo cellular and molecular studies of BCR-ABL-positive ALL with T315I mutation.
|
20471447 |
2010 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
This cell line may provide a useful model for in vitro and in vivo cellular and molecular studies of BCR-ABL-positive ALL with T315I mutation.
|
20471447 |
2010 |
|
Precursor B-cell lymphoblastic leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
Using BCR-ABL-expressing myelogenous and lymphoid cell lines and mouse models of CML and B-cell acute lymphoblastic leukemia (B-ALL) induced by wild-type BCR-ABL or T315I mutant-BCR-ABL, we evaluated the inhibitory effects of omacetaxine on CML and B-ALL.
|
19322212 |
2009 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)(+) acute lymphoblastic leukemia (ALL) patients with T315I mutation.
|
19843886 |
2009 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)(+) acute lymphoblastic leukemia (ALL) patients with T315I mutation.
|
19843886 |
2009 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
|
16990603 |
2007 |
|
Leukemia, Myeloid, Chronic-Phase
|
|
0.030 |
GeneticVariation
|
BEFREE |
These results confirm early assumptions concerning the poor prognosis of chronic phase chronic myelogenous leukemia patients with the T315I mutation who are not eligible for allogeneic transplantation, and demonstrate the need for more therapeutic options.
|
23716543 |
2013 |
|
Leukemia, Myeloid, Chronic-Phase
|
|
0.030 |
GeneticVariation
|
BEFREE |
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
|
22896000 |
2012 |
|
Leukemia, Myeloid, Chronic-Phase
|
|
0.030 |
GeneticVariation
|
BEFREE |
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
|
21030353 |
2010 |
|
Acute lymphocytic leukemia
|
|
0.050 |
GeneticVariation
|
BEFREE |
It suppressed primary Ph+ acute lymphatic leukemia-derived long-term cultures that either displayed nonmutational resistance or harbor the T315I.
|
25394714 |
2015 |
|
Acute lymphocytic leukemia
|
|
0.050 |
GeneticVariation
|
BEFREE |
The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients.
|
22587422 |
2012 |
|
Acute lymphocytic leukemia
|
|
0.050 |
GeneticVariation
|
BEFREE |
This cell line may provide a useful model for in vitro and in vivo cellular and molecular studies of BCR-ABL-positive ALL with T315I mutation.
|
20471447 |
2010 |